Alglucerase
![Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set](http://data.docslib.org/img/264x/135084d885a0ce0d8ef8f9f83426c79a.webp)
![Subject: Zavesca (Miglustat) [Gaucher Disease] Original Effective Date: 8/22/16](http://data.docslib.org/img/264x/446f445602c9e9fe9cdf5742c1040818.webp)
Top View
- Inherited Metabolic Disorders Involving The
- Imiglucerase in the Management of Gaucher Disease Type 1 Open Access to Scientific and Medical Research DOI
- 022458Orig1s000
- Summary Plan Description
- USP Class Example Part D Eligible Drugs* Salt/Ester
- Long-Term Adverse Event Profile from Four Completed Trials of Oral Eliglustat in Adults with Gaucher Disease Type 1 M
- Extract from the Clinical Evaluation Report [2] for Taliglucerase Alfa Rpc
- (12) Patent Application Publication (10) Pub. No.: US 2002/0010208A1 Shashoua Et Al
- Orphan Drug Designation List
- 5.01.576 Drugs for Rare Diseases
- Genzyme Cerezyme (Imiglucerase for Injection) PROPOSED TEXT of the LABELING of the DRUG
- TITLE: Eliglustat Tartrate, Miglustat, Imiglucerase, Velaglucerase Or A
- Alglucerase Injection)
- Elelyso, INN-Taliglucerase Alfa
- Extract from the Clinical Evaluation Report for Eliglustat (As Tartrate)
- Velaglucerase Alfa in the Treatment of Gaucher Disease Type 1
- Imiglucerase in the Treatment of Gaucher Disease: a History and Perspective
- 205494Orig1s000